TABLE 1.
Characteristics of children undergoing liver transplantation, stratified by facility
| Overall | Public sector | Private sector | p‐Value | |
|---|---|---|---|---|
| N | 150 | 61 | 89 | |
| Male (%) | 60 (40.0) | 24 (39.3) | 36 (40.4) | 1.000 |
| Black (%) | 101 (67.3) | 49 (80.3) | 52 (58.4) | .008 |
| Median age at TP (months) [IQR] | 29.18 [15.69, 57.01] | 30.32 [17.23, 68.22] | 28.76 [13.85, 49.35] | .321 |
| Under 18 months of age at TP (%) | 44 (29.3) | 16 (26.2) | 28 (31.5) | .611 |
| Reason for TP (%) | .001 | |||
| Autoimmune | 8 (5.3) | 3 (4.9) | 5 (5.6) | |
| Fulminant liver failure | 22 (14.7) | 17 (27.9) | 5 (5.6) | |
| Idiopathic | 1 (0.7) | 0 (0.0) | 1 (1.1) | |
| Metabolic | 16 (10.7) | 4 (6.6) | 12 (13.5) | |
| Neoplastic | 3 (2.0) | 3 (4.9) | 0 (0.0) | |
| Obstructive | 98 (65.3) | 34 (55.7) | 64 (71.9) | |
| Other | 2 (1.3) | 0 (0.0) | 2 (2.2) | |
| Type of TP (%) | .277 | |||
| Reduced | 4 (2.7) | 3 (4.9) | 1 (1.1) | |
| Related living donor | 77 (51.3) | 31 (50.8) | 46 (51.7) | |
| Split | 39 (26.0) | 18 (29.5) | 21 (23.6) | |
| Whole | 30 (20.0) | 9 (14.8) | 21 (23.6) | |
| Median weight at TP [IQR] | 12.00 [9.35, 16.00] | 13.00 [9.80, 18.00] | 11.10 [9.00, 15.60] | .106 |
| Median weight‐for‐age Z‐score at TP [IQR] | ‐0.80 [‐1.85, ‐0.06] | ‐0.52 [‐1.46, ‐0.08] | ‐1.18 [‐2.17, ‐0.04] | .018 |
| ABO incompatible donor (%) | 5 (3.3) | 5 (8.2) | 0 (0.0) | .022 |
| CMV risk category (%) | .012 | |||
| Low risk (D‐/R‐) | 5 (3.3) | 0 (0.0) | 5 (5.6) | |
| Intermediate risk (D+/R+ or D‐/R+) | 79 (52.7) | 40 (65.6) | 39 (43.8) | |
| High risk (D+/R‐) | 66 (44.0) | 21 (34.4) | 45 (50.6) | |
| Prophylactic regimen used (%) | .801 | |||
| Acyclovir only | 34 (22.7) | 16 (26.2) | 18 (20.2) | .518 |
| Ganciclovir/acyclovir/valganciclovir | 1 (0.7) | 0 (0.0) | 1 (1.1) | – |
| Ganciclovir/valganciclovir | 5 (3.3) | 2 (3.3) | 3 (3.4) | – |
| Valganciclovir | 58 (38.7) | 24 (39.3) | 34 (38.2) | – |
| None | 52 (34.7) | 19 (31.1) | 33 (37.1) | .507 |
| CMV infection (%) | 43 (28.9) | 20 (32.8) | 23 (26.1) | .486 |
| CMV disease (%) | 30 (20.1) | 13 (21.3) | 17 (19.3) | .928 |
| Secondary prophylaxis (%) | 15/43 (34.9) | 6/20 (30.0) | 9/23 (39.1) | .760 |
| Secondary prophylaxis after CMV disease (%) | 13/30 (43.3) | 5/13 (38.4) | 8/17 (47.0) | .711 |
| CMI‐mediated rejection (%) | 58 (38.7) | 19 (41.3) | 39 (58.2) | .115 |
| Antibody‐mediated rejection (%) | 3 (2.0) | 2 (3.3) | 1 (1.1) | .740 |
| Chronic rejection (%) | 7 (4.7) | 4 (6.6) | 3 (3.4) | .607 |
| Any rejection (%) | 69 (46.3) | 25 (41.0) | 44 (50.0) | .358 |
| Died (%) | 45 (30.0) | 20 (32.8) | 25 (28.1) | .663 |
Note: p‐Values are derived from tests that compare public sector to private sector transplant cases, according to type of variable—chi‐squared test or Fisher's exact test, as appropriate, for categorical variables; Student's t‐test for comparison of means; Kruskal‒Wallis test for comparison of medians.
Abbreviations: CMI, cell‐mediated immunity; CMV, human cytomegalovirus; D, donor; IQR, interquartile range; R, recipient; TP, transplant.